Specialty drug spending is rising, contracts are complex, and most employers have limited visibility into what their plan is actually paying. This guide outlines a practical framework for taking control — from demanding transparent contract economics to governing exceptions and planning for the next generation of high-cost therapies.
Why Drug Cost Control Often Fails
Most pharmacy programs focus on the wrong metrics — rebates, discount percentages, and annual guarantees. But those metrics don't answer the most important question: What did the drug actually cost the plan?
Specialty pharmacy represents under 2% of prescriptions but consumes over 50% of pharmacy budgets. Three structural issues drive this.
Rebate-Driven Economics
High rebates make drugs appear cheaper than they are, masking true financial exposure.
Site-of-Care Variation
The same infusion therapy can cost 40% more or less depending on where it is administered.
Exception Creep
Unchecked exception approvals erode formulary discipline and drive costs higher.
A Governance Model Changes This
Effective pharmacy programs rely on structured oversight rather than passive contracting. A practical model applies four disciplines in a repeatable cycle:
Transparency
Clear visibility into drug costs, contract economics, and dispensing patterns.
Definitions
A consistent plan definition of what qualifies as a specialty drug.
Utilization Controls
Structured prior authorization and site-of-care management.
Exception Governance
Formal review and documentation of nonstandard approvals.
These four disciplines make pharmacy spending predictable, auditable, and defensible.
List Price vs. True Cost: The Scale of Exposure
Drug list prices illustrate the scale of financial exposure but do not reflect the true cost to a health plan. Rebates, fees, and contract structures all affect what a plan actually pays — and for many high-cost therapies, those adjustments are minimal or nonexistent.
Examples of current list prices for common specialty drugs:
At the extreme end of the market, gene and cell therapies represent a new category of financial risk:
Step 1: Demand Transparent Economics
Plan sponsors should require contract structures that allow them to clearly understand what they are paying and why. Transparency is the foundation of every other cost management strategy.
At minimum, plans should require visibility into:
Contract Elements to Require
- Ingredient cost
- Dispensing fees
- Spread pricing (the difference between what the PBM charges the plan and what it pays the pharmacy)
- Rebate ownership and pass-through terms
- Administrative fees
- Specialty pharmacy routing decisions
What Transparency Enables
- Reconciling claims against contract promises
- Identifying where costs are inflated
- Holding PBMs accountable to agreed terms
- Proving savings to plan stakeholders
Transparency allows employers to move from trusting the system to verifying it.
Step 2: Define Specialty Drugs Clearly
There is no universal definition of a specialty drug. Many drugs are categorized as specialty primarily because of cost, not clinical complexity — and that ambiguity creates real management problems.
Without a consistent definition, plans cannot effectively manage utilization, set appropriate prior authorization rules, or hold PBMs accountable to contract terms.
Cost Threshold
Does the drug exceed a defined monthly or annual cost?
Clinical Complexity
Does it require special monitoring or clinical oversight?
Route of Administration
Is it injected, infused, or otherwise non-oral?
Handling Requirements
Does it require cold chain, special storage, or limited distribution?
Financial Risk
What is the plan's total exposure if utilization increases?
Once defined, that classification becomes the foundation for every other governance decision — from prior authorization to site-of-care routing to exception review.
Steps 3 & 4: Govern Exceptions and Optimize Site of Care
Two of the most impactful and most overlooked — cost levers in pharmacy management are exception discipline and site-of-care routing. Together, they prevent unnecessary spending at the point of approval and at the point of care.
Governing Exceptions
When exceptions to the formulary are poorly managed, rules erode and costs rise. A structured review process should include:
Clinical Review
Is the drug medically necessary? Does a formulary alternative exist?
Financial Review
What is the net cost versus the formulary option?
Committee Review
Escalate unusual or high-cost exceptions to a governance committee.
Written Documentation
Record the rationale and decision for every exception approved.
Optimizing Site of Care
For infusion drugs, where a patient receives treatment can dramatically affect cost — often billed under the medical benefit and outside standard pharmacy oversight.
Hospital Outpatient
Highest-cost setting; often the default without routing guidance.
Physician Office
Mid-range cost; appropriate for therapies needing close monitoring.
Ambulatory Infusion Center
Lower cost; clinically appropriate for most stable patients.
Home Infusion
Often the lowest-cost option for eligible patients.
Steps 5 & 6: Plan for Advanced Therapies and Support Members
Two forward-looking strategies are increasingly essential for any employer health plan: preparing financially for next-generation therapies, and ensuring members can navigate the system effectively.
Plan for Biosimilars and Gene Therapy
Biosimilar Adoption
Biosimilars are FDA-approved alternatives to brand-name biologic drugs — similar to generics, but for complex injectables. Plans should actively promote biosimilar use through formulary design and prior authorization rules to capture meaningful cost savings.
Gene Therapy Planning
Emerging gene and cell therapies may cost $2M–$4M per treatment. Employers should review stop-loss coverage terms, high-cost therapy policies, reimbursement timing, and coverage rules before a claim occurs. Planning ahead prevents financial shock events.
Support Members Through Navigation
Even the best-designed formulary fails if members face unnecessary barriers. Navigation services help members with prior authorization, specialty pharmacy routing, site-of-care rules, and manufacturer assistance programs — ensuring faster access, plan clarity, and cost avoidance.
Faster Access
Members reach treatment quickly without administrative delays.
Plan Clarity
Members understand their coverage before filling a prescription.
Cost Avoidance
Members use the right channel from the start, reducing escalation.
Navigation is not just a member service — it is a cost management tool.
Measuring Success and Taking Action
Effective pharmacy management focuses on operating metrics — not just rebates. These measures tell you whether your program is actually working.
Specialty Spend
By drug name and diagnosis.
Benefit Utilization
Pharmacy vs. medical benefit.
Site-of-Care Use
Hospital vs. alternative infusion sites.
PA Rates
Approval, denial, and appeal outcomes.
Exception Frequency
How often and by whom exceptions are approved.
Biosimilar Adoption
Percentage of biologic claims using biosimilars.
Net Cost Per Member
True cost after all fees and rebates.
Large-Claim Exposure
Claims exceeding defined thresholds.
Let's Connect
Prescription drug spending doesn't have to be a black box. Whether you're looking to improve contract transparency, define your specialty drug program, or build a governance model that holds up to scrutiny — we can help you get there. Our team works with employers and health plans to bring structure, visibility, and accountability to pharmacy spending.
Design smarter. Reduce friction. Drive adoption.
www.ubf.consulting
800.823.8868
linkedin.com/company/ubf-consulting-inc
How employers can bring visibility, governance, and cost discipline to prescription drug spending